Concurrent gemcitabine and high-intensity focused ultrasound therapy in patients with locally advanced pancreatic cancer

Anti-Cancer Drugs

Volumn 21, Issue 4, 2010, Pages 447-452

  Zhao, Hong ^a   Yang, Guowang ^b   Wang, Daoyuan ^a   Yu, Xiangrong ^d   Zhang, Yu ^a   Zhu, Junqiu ^a   Ji, Yongle ^a   Zhong, Baoliang ^c   Zhao, Wenshuo ^b   Yang, Zhong ^b   Aziz, Fahad ^e  

^a FUDAN UNIVERSITY   (China)

^b BEIJING HOSPITAL OF TRADITIONAL CHINESE MEDICINE AFFILIATED TO CAPITAL MEDICAL UNIVERSITY   (China)

^c PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^d NANJING MEDICAL UNIVERSITY   (China)

^e MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Gemcitabine; High intensity focused ultrasound therapy; Locally advanced pancreatic cancer

Indexed keywords

GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PAIN; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FEMALE; FEVER; FOLLOW UP; HIGH INTENSITY FOCUSED ULTRASOUND; HUMAN; INFECTION; INOPERABLE CANCER; LOCALLY ADVANCED PANCREATIC CANCER; MALE; MUCOSA INFLAMMATION; NAUSEA; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PAIN ASSESSMENT; PANCREAS CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT PLANNING; VISUAL ANALOG SCALE; VOMITING;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; FEMALE; HIGH-INTENSITY FOCUSED ULTRASOUND ABLATION; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 77949422386     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e32833641a7     Document Type: Article

References (46)

1. Jemal A, Siegel R,Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics 2008. CA Cancer J Clin 2008; 58:71-96.
2. Cardenes HR, Chiorean EG, DeWitt J, Schmidt M, Loehrer P. Locally advanced pancreatic cancer: current therapeutic approach. Oncologist 2006; 11:612-623.
3. Moertel CG, Frytak S, Hahn RG, O'Connell MJ, Reitemeier RJ, Rubin J, et al. Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: the gastrointestinal tumor study group. Cancer 1981; 48:1705-1710.
4. Gastrointestinal Tumor Study Group. Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. J Natl Cancer Inst 1988; 80:751-755.
5. Blackstock AW, Bernard SA, Richards F, Eagle KS, Case LD, Poole ME, et al. Phase I trial of twice-weekly gemcitabine and concurrent radiation in patients with advanced pancreatic cancer. J Clin Oncol 1999; 17:2208-2212.
6. McGinn CJ, Zalupski MM, Shureiqi I, Robertson JM, Eckhauser FE, Smith DC, et al. Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 2001; 19:4202-4208.
7. Okusaka T, Ito Y, Ueno H, Ikeda M, Takezako Y, Morizane C, et al. Phase II study of radiotherapy combined with gemcitabine for locally advanced pancreatic cancer. Br J Cancer 2004; 91:673-677.
8. Magnino A, Gatti M, Massucco P, Sperti E, Faggiuolo R, Regge D, et al. Phase II trial of primary radiation therapy and concurrent chemotherapy for patients with locally advanced pancreatic cancer. Oncology 2005; 68:493-499.
9. Crane CH,Winter K, Regine WF, Safran H, Rich TA, CurranW, et al. Phase II study of bevacizumab with concurrent capecitabine and radiation followed by maintenance gemcitabine and bevacizumab for locally advanced pancreatic cancer: Radiation Therapy Oncology Group RTOG 0411. J Clin Oncol 2009; 27:4096-4102.
10. Kovach SJ, Hendrickson RJ, Cappadona CR, Schmidt CM, Groen K, Koniaris LG, et al. Cryoablation of unresectable pancreatic cancer. Surgery 2002; 131:463-464.
11. Patiutko IuI, Barkanov AI, Kholikov TK, Lagoshnyi AT, Li LI, Samoilenko VM, et al. The combined treatment of locally disseminated pancreatic cancer using cryosurgery. Vopr Onkol 1991; 37:695-700.
12. Korpan NN. Cryosurgery: ultrastructural changes in pancreas tissue after low temperature exposure. Technol Cancer Res Treat 2007; 6:59-67.
13. Varshney S, Sewkani A, Sharma S, Kapoor S, Naik S, Sharma A, et al. Radiofrequency ablation of unresectable pancreatic carcinoma: feasibility, efficacy and safety. JOP 2006; 7:74-78.
14. Wang X, Sun J. High-intensity focused ultrasound in patients with late-stage pancreatic carcinoma. Chin Med J (Engl) 2002; 115:1332-1335.
15. Wu F, Wang ZB, Zhu H, Chen WZ, Zou JZ, Bai J, et al. Feasibility of US-guided high-intensity focused ultrasound treatment in patients with advanced pancreatic cancer: initial experience. Radiology 2005; 236:1034-1040.
16. Wu F,Wang ZB, Lu P, Xu ZL, Chen WZ, Zhu H, et al. Activated anti-tumor immunity in cancer patients after high intensity focused ultrasound ablation. Ultrasound Med Biol 2004; 30:1217-1222.
17. Wang ZB,Wu F,Wang ZL, Zhang Z, Zou JZ, Liu C, et al. Targeted damage effects of high intensity focused ultrasound (HIFU) on liver tissues of Guizhou Province miniswine. Ultrason Sonochem 1997; 4:181-182.
18. Burgess SE, Iwamoto T, Coleman DJ, Lizzi FL, Driller J, Rosado A. Histologic changes in porcine eyes treated with high-intensity focused ultrasound. Ann Ophthalmol 1987; 19:133-138.
19. Yang R, Reilly CR, Rescorla FJ, Faught PR, Sanghvi NT, Fry FJ, et al. High-intensity focused ultrasound in the treatment of experimental liver cancer. Arch Surg 1991; 126:1002-1009.
20. Ter Haar G. High intensity ultrasound. Semin Laparosc Surg 2001; 8:77-89.
21. Chen L, Rivens I, ter Haar G, Riddler S, Hill CR, Bensted JP. Histological changes in rat liver tumours treated with high-intensity focused ultrasound. Ultrasound Med Biol 1993; 19:67-74.
22. Leslie TA, Kennedy JE. High-intensity focused ultrasound principles, current uses, and potential for the future. Ultrasound Q 2006; 22:263-272.
23. Chapelon JY, Margonari J, Theillere Y, Gorry F, Vernier F, Blanc E, et al. Effects of high-energy focused ultrasound on kidney tissue in the rat and the dog. Eur Urol 1992; 22:147-152.
24. Adams JB, Moore RG, Anderson JH, Strandberg JD, Marshall FF, Davoussi LR. High-intensity focused ultrasound ablation of rabbit kidney tumors. J Endourol 1996; 10:71-75.
25. Chen W, Wang Z, Wu F, Bai J, Zhu H, Zou J, et al. High intensity focused ultrasound alone for malignant solid tumors. Zhonghua Zhongliu Zazhi 2002; 24:278-281.
26. Chaussy C, Thüroff S. High-intensity focused ultrasound in prostate cancer: results after 3 years. Mol Urol 2000; 4:179-182.
27. Gao Y, Feng J, Wang Q. A clinical study of thermotherapy of HIFU in combination with chemotherapy in treatment of advanced pancreatic cancer. Suzhou Univ J Med Sci 2006; 26:428-430.
28. Vassiliou MC, Feldman LS, Andrew CG, Bergman S, Leffondre K, Stanbridge D, et al. A global assessment tool for evaluation of intraoperative laparoscopic skills. Am J Surg 2005; 190:107-113.
29. A'Hern RP. Sample size tables for exact single-stage phase II designs. Stat Med 2001; 20:859-866.
30. Loehrer P, Powell M, Cardenes H, Wagner L, Brell J, Ramanathan R, et al. A randomized phase III study of gemcitabine in combination with radiation therapy versus gemcitabine alone in patients with localized, unresectable pancreatic cancer: E4201. J ClinOncol 2008; 26:214s. (suppl; abstr 4506).
31. Xiong LL, Hwang JH, Huang XB, Yao SS, He CJ, Ge XH, et al. Early clinical experience using high intensity focused ultrasound for palliation of inoperable pancreatic cancer. JOP 2009; 10:123-129.
32. Goldstein D, Van Hazel G, Walpole E, Underhill C, Kotasek D, Michael M, et al. Gemcitabine with a specific conformal 3D 5FU radiochemotherapy technique is safe and effective in the definitive management of locally advanced pancreatic cancer. Br J Cancer 2007; 97:464-471.
33. Haddock MG, Swaminathan R, Foster NR, Hauge MD, Martenson JA, Camoriano JK, et al. Gemcitabine, cisplatin, and radiotherapy for patients with locally advanced pancreatic adenocarcinoma: results of the North Central Cancer Treatment Group Phase II Study N9942. J Clin Oncol 2007; 25:2567-2572.
34. Hong SP, Park JY, Jeon TJ, Bang S, Park SW, Chung JB, et al. Weekly full-dose gemcitabine and single-dose cisplatin with concurrent radiotherapy in patients with locally advanced pancreatic cancer. Br J Cancer 2008; 98:881-887.
35. Reni M, Cereda S, Balzano G, Passoni P, Rognone A, Zerbi A, et al. Outcome of upfront combination chemotherapy followed by chemoradiation for locally advanced pancreatic adenocarcinoma. Cancer Chemother Pharmacol 2009; 64:1253-1259.
36. Huang PI, Chao Y, Li CP, Lee RC, Chi KH, Shiau CY, et al. Efficacy and factors affecting outcome of gemcitabine concurrent chemoradiotherapy in patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2009; 73:159-165.
37. Molinari M, Helton WS, Espat NJ. Palliative strategies for locally advanced unresectable and metastatic pancreatic cancer. Surg Clin North Am 2001; 81:651-666.
38. Caraceni A, Weinstein SM. Classification of cancer pain syndromes. Oncology (Williston Park) 2001; 15:1627-1643.
39. Farrar JT, Portenoy RK. Neuropathic cancer pain: the role of adjuvant analgesics. Oncology (Williston Park) 2001; 15:1435-1445.
40. Polati E, Finco G, Gottin L, Bassi C, Pederzoli P, Ischia S. Prospective randomized double-blind trial of neurolytic celiac plexus block in patients with pancreatic cancer. Br J Surg 1998; 85:199-201.
41. Lillemoe KD, Cameron JL, Kaufman HS, Yeo CJ, Pitt HA, Sauter PK. Chemical splanchnicectomy in patients with unresectable pancreatic cancer: a prospective randomized trial. Ann Surg 1993; 217:447-457.
42. Ceha HM, van Tienhoven G, Gouma DJ, Veenhof CH, Schneider CJ, Rauws EA, et al. Feasibility and efficacy of high dose conformal radiotherapy for patients with locally advanced pancreatic carcinoma. Cancer 2000; 89:2222-2229.
43. André T, Balosso J, Louvet C, Hannoun L, Houry S, Huguier M, et al. Combined radiotherapy and chemotherapy (cisplatin and 5-fluorouracil) as palliative treatment for localized unresectable or adjuvant treatment for resected pancreatic adenocarcinoma: results of a feasibility study. Int J Radiat Oncol Biol Phys 2000; 46:903-911.
44. Burris HA III, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15:2403-2413.
45. Rothenberg ML, Moore MJ, Cripps MC, Andersen JS, Portenoy RK, Burris HA III, et al. A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol 1996; 7:347-353.
46. Kuwatani M, Kawakami H, Eto K, Haba S, Shiga T, Tamaki N, et al. Modalities for evaluating chemotherapeutic efficacy and survival time in patients with advanced pancreatic cancer: comparison between FDG-PET, CT, and serum tumor markers. Intern Med 2009; 48:867-875.